Clinical trials: Clinical High-risk
MASLD
Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase II clinical trial that consists of two parts.
- Trial name
- NCT07024212
- Testing
- DR10624 Injection
- Where
- 4 sites in China, Hong Kong
- Volunteers
- 110 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Squamous Cell Carcinoma of the Oral Cavity
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
This is a multi-center, randomized, double-blind clinical trial to assess the safety and efficacy of GL-0817 as a means to prevent disease recurrence in patients considered at high-risk following surgery and adjuvant…
- Trial name
- NCT02873819
- Testing
- GL-0817, Hiltonol, Sargramostim
- Where
- 33 sites in United States, Hungary and 5 more
- Volunteers
- 80 people
- Sponsor
- Gliknik Inc.
MCNS, Minimal Change Nephrotic Syndrome (MCNS)
A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome
To compare the therapeutic effect of tacrolimus in combination with low-dose corticosteroid with high-dose corticosteroid alone in patients with minimal-change nephrotic syndrome.
- Trial name
- T-OPTIMUM (NCT01763580)
- Testing
- Tacrolimus, Prednisolone
- Where
- South Korea
- Volunteers
- 144 people
- Sponsor
- Astellas Pharma Korea, Inc.
Prostate Cancer, Castration-resistant Prostate Cancer
A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer
The purpose of this study is to describe patterns in disease management and to describe clinical outcomes, as well as to identify factors influencing physician treatment decisions including reason(s) for treatment choices and…
- Conditions
- Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
- Trial name
- ASPIRE-PCa (NCT02066961)
- Where
- 93 sites in Algeria, Argentina and 25 more
- Volunteers
- 1,533 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Cardiovascular Diseases
A Study of Evacetrapib in High-Risk Vascular Disease
The purpose of the ACCELERATE study is to evaluate the efficacy and safety of evacetrapib in participants with high-risk vascular disease (HRVD).
- Trial name
- ACCELERATE (NCT01687998)
- Testing
- Evacetrapib
- Where
- 444 sites in United States, Argentina and 35 more
- Volunteers
- 12,092 people
- Sponsor
- Eli Lilly and Company
Teeth Color, Teeth Staining
A Clinical Study to Evaluate the Stain Reduction Efficacy of a Non-Fluoride Tooth Whitening Dentifrice Containing Nano-Hydroxyapatite (nHAP) and a High Cleaning Silica Abrasive System Compared to a Commercial Fluoride Non-Whitening Dentifrice as a Negative Control
To determine whether brushing with a non-fluoride tooth whitening dentifrice containing nHAP and a high cleaning silica system produces a greater level of stain reduction as indicated by the Modified Lobene Stain Index (MLSI) for…
- Trial name
- NCT07214038
- Testing
- toothpaste
- Where
- India
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Boka LLC
Blood Glucose, High
Clinical Study to Evaluate the Short Time Efficacy of AP Green Tea Extract Affer High Fat, High Carbohydrate Diet
The objective of this clinical trial is to evaluate the short term effects of single dose AP green tea extracts in subjects with BMI (< 30 kg/m2) and fasting glucose level of > 100 mg/dL after high-fat/high-carbohydrate meal.
- Trial name
- NCT04850326
- Testing
- AP green tea extract
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Amorepacific Corporation
High-grade Squamous Intraepithelial Lesion (HSIL)
Evaluation of NWRD09 for HPV-16 Related Cervical HSIL
This is a randomized, double-blind, placebo controlled Phase 2 study to determine the efficacy and safety of NWRD09 administered by intramuscular (IM) injection in adult women with histologically confirmed cervical high grade…
- Trial name
- NCT07712692
- Testing
- NWRD09 Injection
- Where
- 15 sites in China
- Volunteers
- 156 people
- Sponsor
- Newish Biotech (Wuxi) Co., Ltd.
Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma
A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6
The purpose of this study is to evaluate the safety, tolerability and clinical activity of RO6870810 in combination with venetoclax and when co-administered with rituximab in participants with relapse/refractory (R/R) diffuse…
- Trial name
- NCT03255096
- Testing
- RO6870810, Venetoclax, Rituximab
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 39 people
- Sponsor
- Hoffmann-La Roche
Coronary Artery Disease
Vis-Rx Post-Market Evaluation
Post-market clinical evaluation of the Gentuity High-Frequency Optical Coherence Tomography (HF-OCT) System and the Vis-Rx Micro-Imaging Catheter for use in Percutaneous Coronary Intervention (PCI) procedures.
- Trial name
- Vis-Rx PME (NCT04533503)
- Testing
- HF-OCT Imaging with the Vis-Rx Micro-Imaging Catheter
- Where
- 3 sites in United States
- Volunteers
- 257 people
- Sponsor
- Gentuity, LLC
Chronic Myelogenous Leukemia, Ph1-Positive, Acute Myeloid Leukemia
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
The primary objective of the Phase Ib study is to determine the dose-limiting toxicity (DLT) and maximal tolerated dose (MTD) of BP1001 in combination with dasatinib in patients with with Philadelphia Chromosome Positive (Ph+)…
- Conditions
- Chronic Myelogenous Leukemia, Ph1-Positive, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02923986
- Testing
- BP1001 (varying dose), BP1001 (fixed dose), Dasatinib
- Where
- United States
- Sponsor
- Bio-Path Holdings, Inc.
Glaucoma
Circular Cyclocoagulation Using HIFU With EYEOP1 Device in Glaucoma Patients
The aim of the study is to evaluate the effectiveness and the safety of the cyclocoagulation using HIFU in glaucoma patients
- Trial name
- NCT01791673
- Testing
- Ultrasound glaucoma treatment
- Where
- 5 sites in France
- Volunteers
- 30 people
- Sponsor
- EyeTechCare
Chronic Back Pain, Chronic Back and Leg Pain
High Frequency PNS Stimulation Study for Back and Leg Pain
Prospective, double blinded, randomized, clinical study investigating the effects of high frequency PNS for the treatment of chronic back or back and leg pain.
- Trial name
- NCT03312010
- Testing
- PNS HF
- Where
- 2 sites in Belgium
- Volunteers
- 38 people
- Sponsor
- Curonix LLC
Colorectal Cancer Stage II, Colorectal Cancer Stage III
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer…
- Trial name
- NCT04486378
- Testing
- RO7198457 intravenous (IV), Observational group (no intervention)
- Where
- 85 sites in United States, Belgium and 5 more
- Volunteers
- 327 people
- Sponsor
- BioNTech SE
Abdominal Aortic Aneurysms
AAA Registry: Clinical Outcomes of Highly Angulated anatomY Treated With the Aorfix™ Stent Graft
The ARCHYTAS Registry is a long-term, global, multicenter, non-randomized, prospective, registry designed to collect "on-label" data in real world clinical settings on patients undergoing endovascular repair with the latest…
- Trial name
- ARCHYTAS (NCT02480595)
- Testing
- Stent Graft
- Where
- 37 sites in Czechia, Germany and 4 more
- Volunteers
- 500 people
- Sponsor
- Lombard Medical
Healthy, Breast Cancer
Validation of a Tear-based Screening Assay for Breast Cancer
This study will explore and better understand the value, usage, and benefits of a tear-based screening test for breast cancer as a supplemental tool for screening mammograms.
- Conditions
- Healthy, Breast Cancer, Breast Cancer Female, Health Care Utilization
- Trial name
- NCT04928014
- Testing
- Schirmer Strip
- Where
- United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Namida Lab
Hepatocellular Carcinoma
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
The efficacy and safety of AK104 as adjuvant therapy in hepatocellular carcinoma of high recurrence risk after curative resection.
- Trial name
- NCT05489289
- Testing
- AK104
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Akeso
Postmenopausal
A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture
This is a randomized, double-blind, international multicentre, parallel-controlled phase III clinical study. The study plans to enroll 478 postmenopausal women with osteoporosis at high risk of fracture, whom will be randomized…
- Trial name
- NCT05352516
- Testing
- HLX14, Prolia®
- Where
- 38 sites in China
- Volunteers
- 514 people
- Sponsor
- Shanghai Henlius Biotech
Colorectal Cancer, Advanced Colorectal Neoplasm
A Stool DNA-based SDC2 Methylation Test for the Early Detection of Colorectal Cancer
The primary objective of this clinical trial is to determine the sensitivity and specificity of the EarlyTect® CRC test for detecting CRC, using colonoscopy as the reference method.
- Conditions
- Colorectal Cancer, Advanced Colorectal Neoplasm, Advanced Adenomas, Non-neoplastic Polyps
- Trial name
- NCT05255588
- Testing
- EarlyTect® CRC test
- Where
- South Korea
- Volunteers
- 2,358 people
- Sponsor
- Genomictree, Inc.
Glioma
A Phase 2 Study of HX301 in Patients with High-grade Giloma
The study will include a dose-escalation and dose-expansion component to establish the recommended Phase 2 dose (RP2D) for HX301 in combination with Temozolomide and to evaluate the preliminary antitumor activity of HX301.HX301…
- Trial name
- NCT06703255
- Testing
- HX301+/Temozolomide
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Hangzhou Hanx Biopharmaceuticals, Ltd.